These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 776199)

  • 21. Treatment of acute lymphoblastic leukaemia. Comparison of immunotherapy (B.C.G.), intermittent methotrexate, and no therapy after a five-month intensive cytotoxic regimen ((Concord trial). Preliminary report to the Medical Research Council by the Leukaemia Committee and the Working Party on Leukaemia in Childhood.
    Br Med J; 1971 Oct; 4(5781):189-94. PubMed ID: 4940157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Five-year follow-up of immunotherapy in acute lymphoblastic leukaemia.
    Baker MA; Taub RN
    Lancet; 1977 Jun; 1(8025):1308-9. PubMed ID: 68403
    [No Abstract]   [Full Text] [Related]  

  • 23. [Simple propositions in the treatment of acute lymphoblastic leukaemia (author's transl)].
    Amiel JL
    Nouv Presse Med; 1977 Sep; 6(29):2595-7. PubMed ID: 409993
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapy of human acute leukaemia.
    Alexander P; Powles R
    Clin Haematol; 1978 Jun; 7(2):275-94. PubMed ID: 28191
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cessation of therapy during complete remission of childhood acute lymphocytic leukemia.
    Aur RJ; Simone JV; Husto HO; Verzosa MS; Pinkel D
    N Engl J Med; 1974 Dec; 291(23):1230-4. PubMed ID: 4528982
    [No Abstract]   [Full Text] [Related]  

  • 26. Immunotherapy in the treatment of acute leukaemia.
    Whittaker JA
    Br J Haematol; 1980 Jun; 45(2):187-93. PubMed ID: 6934004
    [No Abstract]   [Full Text] [Related]  

  • 27. [HLA phenotypes in patients surviving a long time after immunotherapy with BCG for acute childhood lymphoblastic leukemia. Arguments in favor of the existance of a gene for immune response in human leukemia].
    Tursz T; Hors J; Lipinski M; Amiel JL
    C R Acad Hebd Seances Acad Sci D; 1977 Dec; 285(16):1585-7. PubMed ID: 417839
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Studies of leukemia specific antigen and immunotherapy of acute leukemia with cell-wall skeleton of BCG.
    Ohno R; Ezaki K; Morishima Y; Kodera Y; Yamada K
    Nihon Ketsueki Gakkai Zasshi; 1978 Dec; 41(6):1134-41. PubMed ID: 87101
    [No Abstract]   [Full Text] [Related]  

  • 29. [Phagocytic activity of the neutrophils and monocytes during remission of acute leukemia after chemotherapy and immunotherapy with BCG vaccine and levamisole].
    Dosimov ZhB; Skorobogatova OV; Rumiantsev AG; Eremeev VS
    Pediatriia; 1981; (8):26-8. PubMed ID: 6945550
    [No Abstract]   [Full Text] [Related]  

  • 30. Colony-forming ability of marrow from patients receiving immunotherapy during chemotherapy-induced remission in acute myeloid leukaemia.
    Gordon MY; Powles RL; Douglas ID
    J Clin Pathol; 1977 Jan; 30(1):70-5. PubMed ID: 320231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term remission in acute lymphoid leukemia patients on maintenance chemoimmunotherapy.
    Eremeev VS; Rumyantsev AG; Akimova GV; Osipov SG; Kislyak NS; Bergolz VM
    Neoplasma; 1981; 28(2):219-21. PubMed ID: 6942239
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined drug and immunostimulation therapy against a syngeneic murine leukemia.
    Pearson JW; Chirigos MA; Chaparas SD; Sher NA
    J Natl Cancer Inst; 1974 Feb; 52(2):463-8. PubMed ID: 4593139
    [No Abstract]   [Full Text] [Related]  

  • 33. [Results of immunotherapy of acute leukemias with BCG vaccine of Polish production].
    Kardaszewicz E; Japa J
    Acta Haematol Pol; 1975; 6(2):149-55. PubMed ID: 1057344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Immunotherapy of cancer with BCG].
    Yamamura Y; Azuma I
    Nihon Rinsho; 1974 Mar; 32(3):542-53. PubMed ID: 4603604
    [No Abstract]   [Full Text] [Related]  

  • 35. [BCG immunotherapy in children with acute lymphocytic leukemia in continuous remission after 3 years of intensive chemotherapy (protocol C-70) (author's transl)].
    Ortega JJ; Javier G
    Med Clin (Barc); 1982 Mar 1-15; 78(5):183-8. PubMed ID: 6952060
    [No Abstract]   [Full Text] [Related]  

  • 36. Safe method of collecting leukaemia cells from patients with acute leukaemia for use as immunotherapy.
    Powles RL; Lister TA; Oliver RT; Russell J; Smith C; Kay HE; McElwain TJ; Fairley GH
    Br Med J; 1974 Nov; 4(5941):375-9. PubMed ID: 4529647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of systemic immunity adjuvants in the prophylaxis or therapy of cancer.
    Mathé G; Halle-Pannenko O; Bourut C; Hiu IJ
    Johns Hopkins Med J Suppl; 1974; 3():85-102. PubMed ID: 4154074
    [No Abstract]   [Full Text] [Related]  

  • 38. Active specific immunotherapy for acute myelogenous leukaemia.
    Powles R
    Johns Hopkins Med J Suppl; 1974; 3():333-40. PubMed ID: 4609353
    [No Abstract]   [Full Text] [Related]  

  • 39. L2C leukemia: a model of human acute leukemia.
    Murphy SG; LoBuglio AF
    Fed Proc; 1977 Aug; 36(9):2281-5. PubMed ID: 328309
    [No Abstract]   [Full Text] [Related]  

  • 40. Comparison of HLA phenotypes in long-term survivors with acute lymphoblastic leukemia treated with immunotherapy versus chemotherapy.
    Tursz T; Hors J; Lipinski M; Amiel JL; Mathé G
    Recent Results Cancer Res; 1982; 80():26-8. PubMed ID: 7036290
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.